World Infertility Device Leader (OTC:IVOB)

World Health Organization statistics imply that infertility and sterility will be the third most serious diseases in the 21st century after cancer and cardiovascular diseases, according to a Life Times report.

InvoBioscience (OTC:IVOB) is engaged in providing its InvoCell technology to help infertile couples have a baby. It has one principal product, the manufacturing and distribution of the InvoCell technology.

InvoBioscience has rapidly conquered many countries with a big market potential. Distributor contracts have been signed all over the world; registration process for clearance when it is needed has been started as well. Their strategy to focus on other countries first rather than the classic USA FDA path was very well done. InvoBioscience’s incomes have started to growth on each part of the world.

While InvoBioscience has many distribution agreements coming up or already signed for many countries, this article focuses here only on the biggest markets potential.

Chinese Market

Couples in China, the world’s most populous nation, are having difficulty conceiving. Infertility in the country has risen from 12.5 to 15 percent but that number could climb quickly to about 20, according to a report released recently at a forum in Beijing.

However the price tags are prohibitive for most people – worth several or many times their annual salary – but an increasing number of Chinese families are now able to afford the treatment.

“Actually more than 10 million Chinese families need artificial fertilization”, according to Xinhua news agency.

Professor Lu Bodong, vice president of the Second Hospital of Zhenjiang Chinese Medical University in Hangzhou, east China’s Zhejiang Province, attributes rising infertility rates to stressful and unhealthy lifestyles that include excessive drinking and smoking, over-indulgence, and also environmental problems, all of which are side effects of China’s dramatic social and economic changes.

“Now, more and more people are becoming open to fertility treatment. There are more than 200 reproduction centers in China, but this is not enough to meet the demand.”

“The industry is believed to be huge in China.” says Zhao Lixin, deputy director of the reproduction center in east China’s Shandong Province Hospital.

InvoBioscience has signed a distributor contract with The Progressive Group; they are one of the larger med device and equipment distributors in this area. The registration process has been started with Chinese FDA authorities; INVO is waiting to know if a trial will need to be done in China or if the FDA will look to the European guidelines of acceptance and grade InvoCell as a Class II med device.

Indian Market

India has a population of 1.15 Billion people with an estimated 14 million infertile couples. India has power infrastructure issues throughout most of the country therefore traditional IVF is not widely available and unreliable to support. InvoCell’s lack of reliance on electric power will make infertility treatment an option that most of the population does not currently have.

India does NOT need any sort of regulatory clearance.

InvoBioscience is working with potential distributors and has trained and most likely continue to train doctors in India over the next few months.

Related Articles:

1. ARCA Submits New SPA (NASDAQ:ABIO)
2. Medifocus Begins OTC Trading (OTC:MDFZE)
3. IntriCon’s New CDM Device (NASDAQ:IIN)
4. Neogen’s New Subsidiary (NASDAQ:NEOG)
5. BioElectronics Making BIG News This Week (BIEL)

Pages: 1 2